Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia
Identifieur interne : 000D63 ( Main/Corpus ); précédent : 000D62; suivant : 000D64Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia
Auteurs : Stefano Zoccolella ; Claudia Dell'Aquila ; Giovanni Abruzzese ; Angelo Antonini ; Ubaldo Bonuccelli ; Margherita Canesi ; Silvano Cristina ; Roberta Marchese ; Claudio Pacchetti ; Roberto Zagaglia ; Giancarlo Logroscino ; Giovanni Defazio ; Paolo Lamberti ; Paolo LivreaSource :
- Movement Disorders [ 0885-3185 ] ; 2009-05-15.
English descriptors
- KwdEn :
Abstract
Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; P < 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; P = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (<12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22511
Links to Exploration step
ISTEX:4825E832B19BD72D903206ADEE42E88D5E0E1F54Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title><author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name><affiliation><mods:affiliation>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Dell Aquila, Claudia" sort="Dell Aquila, Claudia" uniqKey="Dell Aquila C" first="Claudia" last="Dell'Aquila">Claudia Dell'Aquila</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Abruzzese, Giovanni" sort="Abruzzese, Giovanni" uniqKey="Abruzzese G" first="Giovanni" last="Abruzzese">Giovanni Abruzzese</name><affiliation><mods:affiliation>Department of Neurosciences, University of Genova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation><mods:affiliation>Department of Neuroscience, University of Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Cristina, Silvano" sort="Cristina, Silvano" uniqKey="Cristina S" first="Silvano" last="Cristina">Silvano Cristina</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Marchese, Roberta" sort="Marchese, Roberta" uniqKey="Marchese R" first="Roberta" last="Marchese">Roberta Marchese</name><affiliation><mods:affiliation>Department of Neurosciences, University of Genova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zagaglia, Roberto" sort="Zagaglia, Roberto" uniqKey="Zagaglia R" first="Roberto" last="Zagaglia">Roberto Zagaglia</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Logroscino, Giancarlo" sort="Logroscino, Giancarlo" uniqKey="Logroscino G" first="Giancarlo" last="Logroscino">Giancarlo Logroscino</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Defazio, Giovanni" sort="Defazio, Giovanni" uniqKey="Defazio G" first="Giovanni" last="Defazio">Giovanni Defazio</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4825E832B19BD72D903206ADEE42E88D5E0E1F54</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22511</idno><idno type="url">https://api.istex.fr/document/4825E832B19BD72D903206ADEE42E88D5E0E1F54/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title><author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name><affiliation><mods:affiliation>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Dell Aquila, Claudia" sort="Dell Aquila, Claudia" uniqKey="Dell Aquila C" first="Claudia" last="Dell'Aquila">Claudia Dell'Aquila</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Abruzzese, Giovanni" sort="Abruzzese, Giovanni" uniqKey="Abruzzese G" first="Giovanni" last="Abruzzese">Giovanni Abruzzese</name><affiliation><mods:affiliation>Department of Neurosciences, University of Genova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation><mods:affiliation>Department of Neuroscience, University of Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Cristina, Silvano" sort="Cristina, Silvano" uniqKey="Cristina S" first="Silvano" last="Cristina">Silvano Cristina</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Marchese, Roberta" sort="Marchese, Roberta" uniqKey="Marchese R" first="Roberta" last="Marchese">Roberta Marchese</name><affiliation><mods:affiliation>Department of Neurosciences, University of Genova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pacchetti, Claudio" sort="Pacchetti, Claudio" uniqKey="Pacchetti C" first="Claudio" last="Pacchetti">Claudio Pacchetti</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zagaglia, Roberto" sort="Zagaglia, Roberto" uniqKey="Zagaglia R" first="Roberto" last="Zagaglia">Roberto Zagaglia</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Logroscino, Giancarlo" sort="Logroscino, Giancarlo" uniqKey="Logroscino G" first="Giancarlo" last="Logroscino">Giancarlo Logroscino</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Defazio, Giovanni" sort="Defazio, Giovanni" uniqKey="Defazio G" first="Giovanni" last="Defazio">Giovanni Defazio</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Bari, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-15">2009-05-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1028">1028</biblScope><biblScope unit="page" to="1033">1033</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4825E832B19BD72D903206ADEE42E88D5E0E1F54</idno><idno type="DOI">10.1002/mds.22511</idno><idno type="ArticleID">MDS22511</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dementia</term><term>folate</term><term>homocysteine</term><term>progression</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; P < 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; P = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (<12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Stefano Zoccolella MD</name><affiliations><json:string>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</json:string></affiliations></json:item><json:item><name>Claudia dell'Aquila MD</name><affiliations><json:string>Department of Neurological Sciences, University of Bari, Italy</json:string></affiliations></json:item><json:item><name>Giovanni Abruzzese MD</name><affiliations><json:string>Department of Neurosciences, University of Genova, Italy</json:string></affiliations></json:item><json:item><name>Angelo Antonini MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</json:string></affiliations></json:item><json:item><name>Ubaldo Bonuccelli MD</name><affiliations><json:string>Department of Neuroscience, University of Pisa, Italy</json:string></affiliations></json:item><json:item><name>Margherita Canesi MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</json:string></affiliations></json:item><json:item><name>Silvano Cristina MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</json:string></affiliations></json:item><json:item><name>Roberta Marchese MD</name><affiliations><json:string>Department of Neurosciences, University of Genova, Italy</json:string></affiliations></json:item><json:item><name>Claudio Pacchetti MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</json:string></affiliations></json:item><json:item><name>Roberto Zagaglia MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</json:string></affiliations></json:item><json:item><name>Giancarlo Logroscino MD, PhD</name><affiliations><json:string>Department of Neurological Sciences, University of Bari, Italy</json:string></affiliations></json:item><json:item><name>Giovanni Defazio MD</name><affiliations><json:string>Department of Neurological Sciences, University of Bari, Italy</json:string></affiliations></json:item><json:item><name>Paolo Lamberti MD</name><affiliations><json:string>Department of Neurological Sciences, University of Bari, Italy</json:string></affiliations></json:item><json:item><name>Paolo Livrea MD</name><affiliations><json:string>Department of Neurological Sciences, University of Bari, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>homocysteine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>folate</value></json:item></subject><articleId><json:string>MDS22511</json:string></articleId><language><json:string>eng</json:string></language><abstract>Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; P > 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; P = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (>12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.491</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1432</abstractCharCount><pdfWordCount>3755</pdfWordCount><pdfCharCount>24373</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>228</abstractWordCount></qualityIndicators><title>Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>1033</last><first>1028</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22511</json:string></doi><id>4825E832B19BD72D903206ADEE42E88D5E0E1F54</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4825E832B19BD72D903206ADEE42E88D5E0E1F54/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4825E832B19BD72D903206ADEE42E88D5E0E1F54/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4825E832B19BD72D903206ADEE42E88D5E0E1F54/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The authors report no conflicts of interest.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title><author><persName><forename type="first">Stefano</forename><surname>Zoccolella</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</affiliation></author><author><persName><forename type="first">Claudia</forename><surname>dell'Aquila</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation></author><author><persName><forename type="first">Giovanni</forename><surname>Abruzzese</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University of Genova, Italy</affiliation></author><author><persName><forename type="first">Angelo</forename><surname>Antonini</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</affiliation></author><author><persName><forename type="first">Ubaldo</forename><surname>Bonuccelli</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neuroscience, University of Pisa, Italy</affiliation></author><author><persName><forename type="first">Margherita</forename><surname>Canesi</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</affiliation></author><author><persName><forename type="first">Silvano</forename><surname>Cristina</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation></author><author><persName><forename type="first">Roberta</forename><surname>Marchese</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University of Genova, Italy</affiliation></author><author><persName><forename type="first">Claudio</forename><surname>Pacchetti</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation></author><author><persName><forename type="first">Roberto</forename><surname>Zagaglia</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation></author><author><persName><forename type="first">Giancarlo</forename><surname>Logroscino</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation></author><author><persName><forename type="first">Giovanni</forename><surname>Defazio</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Lamberti</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy===</p></note><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Livrea</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1028">1028</biblScope><biblScope unit="page" to="1033">1033</biblScope></imprint></monogr><idno type="istex">4825E832B19BD72D903206ADEE42E88D5E0E1F54</idno><idno type="DOI">10.1002/mds.22511</idno><idno type="ArticleID">MDS22511</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; P < 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; P = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (<12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>homocysteine</term></item><item><term>dementia</term></item><item><term>progression</term></item><item><term>folate</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-09">Received</change><change when="2009-01-29">Registration</change><change when="2009-05-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4825E832B19BD72D903206ADEE42E88D5E0E1F54/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v24:7</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2009-05-15">15 May 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="11" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22511</doi><idGroup><id type="unit" value="MDS22511"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-09"></event><event type="manuscriptRevised" date="2009-01-19"></event><event type="manuscriptAccepted" date="2009-01-29"></event><event type="firstOnline" date="2009-04-07"></event><event type="publishedOnlineFinalForm" date="2009-05-28"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-04-07"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.3 mode:FullText" date="2014-07-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.3 mode:FullText" date="2014-07-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1028</numbering><numbering type="pageLast">1033</numbering></numberingGroup><correspondenceTo>Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22511.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="38"></count><count type="wordTotal" number="4675"></count></countGroup><titleGroup><title type="main" xml:lang="en">Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia<link href="#fn1"></link></title><title type="short" xml:lang="en">Hyperhomocysteinemia in Parkinson's Disease Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Stefano</givenNames><familyName>Zoccolella</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Claudia</givenNames><familyName>dell'Aquila</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Giovanni</givenNames><familyName>Abruzzese</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Angelo</givenNames><familyName>Antonini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Ubaldo</givenNames><familyName>Bonuccelli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Margherita</givenNames><familyName>Canesi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Silvano</givenNames><familyName>Cristina</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Roberta</givenNames><familyName>Marchese</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Claudio</givenNames><familyName>Pacchetti</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Roberto</givenNames><familyName>Zagaglia</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Giancarlo</givenNames><familyName>Logroscino</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Giovanni</givenNames><familyName>Defazio</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Paolo</givenNames><familyName>Lamberti</familyName><degrees>MD</degrees></personName><contactDetails><email>lamberti@neurol.uniba.it</email></contactDetails></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Paolo</givenNames><familyName>Livrea</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences, University of Bari, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurosciences, University of Genova, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neuroscience, University of Pisa, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">homocysteine</keyword><keyword xml:id="kwd3">dementia</keyword><keyword xml:id="kwd4">progression</keyword><keyword xml:id="kwd5">folate</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; <i>P</i> < 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; <i>P</i> = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (<12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: The authors report no conflicts of interest.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Hyperhomocysteinemia in Parkinson's Disease Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia</title></titleInfo><name type="personal"><namePart type="given">Stefano</namePart><namePart type="family">Zoccolella</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinic of Nervous System Diseases, Medical and Neurological Sciences, Azienda Ospedaliero‐Universitaria Ospedali Riuniti, University of Foggia, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudia</namePart><namePart type="family">dell'Aquila</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Abruzzese</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University of Genova, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angelo</namePart><namePart type="family">Antonini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ubaldo</namePart><namePart type="family">Bonuccelli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neuroscience, University of Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Margherita</namePart><namePart type="family">Canesi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Silvano</namePart><namePart type="family">Cristina</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roberta</namePart><namePart type="family">Marchese</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University of Genova, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudio</namePart><namePart type="family">Pacchetti</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roberto</namePart><namePart type="family">Zagaglia</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, CRIMP IRCCS C. Mondino Institute of Neurology, Pavia, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giancarlo</namePart><namePart type="family">Logroscino</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Defazio</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Lamberti</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation><description>Correspondence: Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy===</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Livrea</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, University of Bari, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-05-15</dateIssued><dateCaptured encoding="w3cdtf">2008-10-09</dateCaptured><dateValid encoding="w3cdtf">2009-01-29</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">38</extent><extent unit="words">4675</extent></physicalDescription><abstract lang="en">Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was to evaluate the association between plasma Hcy levels and dementia in PD. We performed a multicenter cross‐sectional study on patients with PD with (PDD) and without (PDnD) dementia and age‐ and sex‐matched healthy controls. We compared Hcy levels in patients with PDD and PDnD and healthy controls, and we performed logistic regression analysis to search for an association between the presence of dementia and increased Hcy levels in PD. Patients with PD (121), PDD (42), and PDnD (79), and age‐ and sex‐matched controls (154) were enrolled. Hcy levels were higher in patients with PD compared to controls (17.5 μmol/L ± 10.2 vs. 11 ± 4.1; P < 0.00001). Among patients with PD, Hcy levels were higher in the PDD group compared to the PDnD group (20.7 μmol/L ± 12.1 vs. 15.8 ± 8.5; P = 0.002). In a multivariate logistic regression model, higher Hcy levels [Odds ratios comparing the top (>18.9 μmol/L) with the bottom tertile (<12.4 μmol/L): 3.68; 95% CI: 1.14–11.83] were significantly associated with dementia. These data support the association between elevated Hcylevels and the presence of dementia in PD. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The authors report no conflicts of interest.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>homocysteine</topic><topic>dementia</topic><topic>progression</topic><topic>folate</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1028</start><end>1033</end><total>6</total></extent></part></relatedItem><identifier type="istex">4825E832B19BD72D903206ADEE42E88D5E0E1F54</identifier><identifier type="DOI">10.1002/mds.22511</identifier><identifier type="ArticleID">MDS22511</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4825E832B19BD72D903206ADEE42E88D5E0E1F54
|texte= Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia
}}
| This area was generated with Dilib version V0.6.23. |  |